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Abstract: 
Background: Discrete Choice Experiment [DCE], Conjoint Analysis [CA], or Adaptive Conjoint Analysis 
[ACA] methods are increasingly applied to obtain patient, clinician or community preferences in 
nephrology. This study systematically reviews the above mentioned published choice studies 
providing an overview of the issues addressed, methods, and findings. 
Methods: Choice studies relating to nephrology were identified using electronic databases, including 
Medline, Embase, PsychINFO and Econlit from 1990 to 2015. For inclusion in the review, studies had 
to primarily relate to kidney disease and include results from statistical (econometric) analyses of 
respondents’ choice or preference. Studies meeting the inclusion criteria were assessed against a 
range of systematic review criteria, and methods and results summarised. 
Results: We identified 14 eligible studies from Europe, Australasia, North America, and Asia, 
reporting preferences for treatment or screening, patient experiences, quality of life, health 
outcomes and priority setting frameworks. Specific contexts included medical interventions in kidney 
transplantation and renal cell carcinoma, health policies for organ donation and allocation, dialysis 
modalities and end-of-life care; using a variety of statistical models. The characteristics of ‘time’ (i.e. 
transplant waiting time, dialysis hours, transport time) and ‘quality of life’ (pre and post-transplant, 
or pre and post-dialysis) consistently influenced patient and clinician preferences across the choice 
studies. 
Conclusions: Discrete choice experiments are increasingly used to obtain information about key 
preferences in kidney transplantation and dialysis. These study methods provide quantitative 
information about respondents’ trade-offs between conflicting clinical and policy objectives, and can 
establish how preferences vary among stakeholder groups. 
 
Keywords: Conjoint Analysis, Discrete Choice Experiment, Dialysis, Transplantation, Kidney Disease, 
Preferences. 
Summary sentences: 
Discrete Choice Experiments and Conjoint Analyses are increasingly used to study preferences in 
nephrology about organ donation and organ allocation decisions, and dialysis modality preferences.  
Such choice studies can assess preferences for treatments and policies from a variety of 
stakeholders including nephrologists, patients, caregivers, and the broader community.  
They highlight the trade-offs people make between multiple objectives in transplantation and 
dialysis care. 
Introduction:  
Every day in nephrology, clinicians and patients face difficult decisions about treatment options, best 
practice care, and the ‘right’ use of resources.  Discrete Choice Experiments (DCE), Conjoint Analysis 
(CA) and Adaptive Conjoint Analysis (ACA) studies systematically quantify preferences for 
alternatives, and measure the trade-offs people make between the characteristics of each 
alternative. They are grounded in Lancaster’s theory of demand,[1] which assumes demand for 
goods and services, including health services can be related to demand for individual characteristics 
of the goods or services. Further theoretical details[2] are provided in the technical appendix (see 
Appendix A.3).  
 
Systematic reviews of the application of DCE, CA, or ACA literature in healthcare from 1990 to 
2012[3] reported rapid growth in the application of such techniques from an average of just over 3 
per year between 1990-2000 to 48 per year between 2009-2012. The aims of this study were to 
review the nephrology DCE, CA, and ACA literature published since 1990; to highlight the key trade-
offs patients, clinicians, and   other groups make in this context; and undertake a detailed systematic 
outline of study methodology.  
 
Methods 
Using keywords including (Nephrology OR Kidney OR Renal) AND (Discrete Choice OR Conjoint 
Analysis) in Medline, Embase, PsychINFO and Econlit from 1
st
 January 1990 to 31
st
 December 2015 
we identified studies that used DCE, CA, or ACA methodology, applied to any research question 
relating to nephrology.  Primary studies were included in the systematic review if they contained 
empirical (statistical or econometric) analyses; study protocols, conference abstracts, reviews and 
opinions pieces were excluded. We followed criteria used in two previous reviews for study designs 
of this type,[3, 4] and further details are within the electronic appendices.  
 
DCE and CA survey studies involve a comparison between 2 or 3 alternatives. The characteristics 
(known as attributes) of these alternatives are identical, but levels of characteristics change. Figure 1 
provides an example of a DCE scenario, and Table 1 displays all of the attribute levels. With both DCE 
and CA formats, the range of choices faced is pre-determined before choices are made. In contrast, 
ACA methods use similar choices but are ‘adaptive’ because scenarios are generated by an adaptive 
computer programme taking into account previous responses. These approaches (DCE, CA, and ACA) 
have an advantage over other ranking or rating techniques such as Likert scale because they 
facilitate a relative quantitative valuation of different characteristics as opposed to trying to value or 
rank the alternative as a ‘whole.’ 
 
Results 
We identified 14 eligible studies from Europe, Australia, New Zealand, North America, and Asia, that 
reported preference information for a wide range of stakeholder groups including patients, clinicians 
/healthcare professionals, caregivers, donors, relatives of deceased donors, and the general 
community. Studies elicited preferences for medical interventions in kidney transplantation, health 
policies for organ donation and allocation, dialysis modalities, and end-of-life care. Methodological 
criteria for each study are listed in Tables S1-S15. We provide information about the country of 
analysis, and category or categories of primary choice studies (Table 2), as reported in previous 
systematic reviews of DCE, CA, and ACA literature in healthcare.  
 
Transplantation studies 
One CA in the United States among 175 patients,[5] investigated the acceptability of receiving a 
kidney from a donor at increased risk of blood-borne viral infection (DIRVI). The analysis contained 3 
attributes relating to HIV infection risk, donor age, and transplant waiting time. Findings suggested 
longer waiting time (P<0.01), lower donor age (P<0.01), lower donor HIV risk, participant being on 
dialysis (P<0.01), and older participant age (P=0.04), significantly affected preferences. Overall 42 
respondents (24%) would not accept a DIRVI kidney in any scenario; 103 (59%) would accept a DIRVI 
kidney in some scenarios; and 31 (18%) would accept a DIRVI kidney in all scenarios. Patients were 
more likely to accept DIRVI kidneys when the waiting time was longer (P<0.01); the donor was 
younger (P<0.01); and HIV risk was lower (P<0.01). Patients on dialysis (P<0.01) and older patients 
(P<0.01) would be more likely to accept DIRVI kidneys. 
 
Another DCE  in the UK assessed preferences of 908 patients for 6 kidney transplant allocation 
criteria.[6] Findings were presented in terms of a marginal rate of substitution (MRS) that is, a trade-
off relative to waiting an additional year for a kidney transplant. Results suggested that among 
patients who were not from ethnic minority group, all attributes were significant. Findings suggested 
a pronounced preference for prioritising patients with moderate not severe diseases affecting life 
expectancy (MRS = 15.93), but paradoxically no preference for ‘no diseases versus moderate 
diseases,’ affecting life expectancy. Other significant attributes included a 1% improvement in kidney 
survival (MRS = 1.54); having an extra dependent adult or child (MRS = 1.35); a one-year reduction in 
recipient age (MRS = 0.16); having no disease other than kidney disease affecting quality of life (MRS 
= -2.48); and having moderate rather than severe diseases affecting quality of life (MRS = 4.08), as 
was transplant waiting time (MRS = 1). Those who were not from ethnic minorities would prioritise 
transplants to patients with a better tissue match to the donor, whereas non-white ethnic mi.  
 
In a later analysis[7] the same DCE was applied to 908 patients, 41 carers, 113 healthcare 
professionals, and 48 live donors /relatives of deceased donors. Similarly, findings suggested a 
pronounced preference for prioritising patients with moderate, not severe, diseases affecting life 
expectancy (MRS = 15.32). A 1% improvement in kidney survival (MRS = 1.41); having an extra 
dependent adult or child (MRS = 1.43); a one year reduction in recipient age (MRS = 0.16); having no 
diseases other than kidney disease affecting quality of life (MRS = -2.73); and having moderate 
rather than severe diseases affecting quality of life (MRS = 4.18) were also valued relative to a 1 year 
transplant wait. Healthcare professionals’ valued prioritising patients with better tissue matches 
lower than patients but prioritised younger recipients and those with dependents higher. They 
prioritised those with none versus moderate diseases, affecting life expectancy whereas patients did 
not, and they prioritised those with moderate rather than severe diseases higher than patients. 
Assessment of preferences for live donors or relatives of deceased donors, and carers, was limited 
by small sample sizes.  
 
A DCE assessed community preferences for the allocation of donor organs for transplantation 
(including kidneys and other organs) in Australia[8] using a sample of 2,051 community respondents. 
This study had 15 attributes. Findings suggested most of the variables for transplant allocation 
criteria were significant at the 0.001 level, with the exception of having previous cancer, which was 
significant at the 1% level (p=0.01); recipient sex, and having diabetes which were non-significant 
(p>0.05). Mixed logit analysis suggested that allocation to people aged 5 (β = 0.662), 15 (β = 0.562), 
or 25 (β = 0.380), was preferred compared to recipients aged 40 (β = -0.163), whilst allocation to 
those aged 55 (β = -0.277), or 70 (β = -1.164), was less preferred to those aged 40. Those with 
previous transplant(s) (β = -0.146), and those who did not follow their doctor’s advice (β = -0.059), 
were given a lower priority. Those with caring responsibilities (β = 0.351), or whose family were 
registered as donors (β = 0.186), were prioritised more; those with long waiting times were 
prioritized (β = 0.042); those with lower life expectancy without a transplant (β = -0.87), and higher 
life expectancy post-transplant (β = 0.058), were prioritised; those with lower quality of life without 
a transplant (β = 0.057), and higher quality of life post-transplant (β = 0.112), were prioritised. Those 
with comorbidities such as diabetes and previous cancer (β =- 0.088), and hepatitis and other viral 
diseases which were being treated (β = -0.217), were prioritised less. Compared to non-smokers, ex-
smokers (β = -0.265), or current smokers (β = -0.751), were given lower priority, as were those 
consuming alcohol occasionally (β = -0.093) or more than 5 nights a week (β = -0.350).  Obese people 
(β = -0.266), compared to non-obese people were also given lower priority. 
 
A second DCE analysis[9] investigated the preferences of 2,005 Australian community respondents 
for organ donation policy. The impact of 8 policy attributes was assessed. The analysis suggested 
that the type of donation consent system and availability of family priority for transplants in the 
future did not influence community preferences. Results were presented in terms of odds ratios 
(OR), whereby an OR >1 for an attribute suggested that as the level of the attribute increased, policy 
alternative A was preferred over policy B. Respondents favoured a policy where the donor's family 
still had some, but not all, involvement in the final donation decision; however a policy where family 
always has the final say (OR), 0.25; 95% confidence interval [95%CI], 0.21-0.28), or never has the 
final say (OR, 0.50; 95% CI, 0.44-0.56) was significantly less preferred. Respondents also preferred a 
policy where the registration process was easy (OR, 1.16; 95%CI, 1.09-1.24), e.g. sending all adults a 
registration form and reply paid envelope; where reconfirmation of donation intent was less 
frequent (for example, annual confirmation: OR, 0.88; 95%CI, 0.78-0.98); where there was a direct 
payment (OR range 1.19-1.32) or reimbursement of funeral expenses (OR range 1.18-1.55); and 
where there was some formal recognition of donation, for example, a letter to the donor's family 
(OR, 1.14; 95%CI, 1.04-1.27), or the donor's name placed on a memorial (OR, 1.29; 95%CI, 1.14-
1.45).  
 Dialysis studies 
A CA in the US examined the willingness of patients to switch dialysis modality from conventional to 
more frequent dialysis.[10] The authors established the impact of 4 attributes including life 
expectancy, quality of life, the annual number of hospitalisations, and transport time. All 4 attributes 
were significantly associated with a willingness to switch to daily haemodialysis in the hypothesised 
direction. Findings showed that 44% of respondents receiving conventional haemodialysis 3 times 
per week would not switch to daily 6 times per week haemodialysis regardless of the health 
benefits. Of the 56% who said they might switch to this regimen, the majority would only switch for 
substantive health benefits. 
 
A second dialysis DCE investigated public preferences for the location of dialysis facilities for 
residents of Greenland.[11] This involved 3 attributes including recruitment of nephrologists, 
location of patient accommodation, and increase in taxation required for dialysis. All the variables 
relating to these 3 attributes were significant at the 1% level, and standard deviations were 
significant for all random parameter logit variables (indicating statistically significant preference 
heterogeneity - see appendix A.2 for details). A key finding was that hypothetical alternatives 
involving treatment in Greenland (versus treatment in Denmark) were chosen in nearly two-thirds of 
cases, implying a ‘slight tendency’ to favour treatment in Greenland despite increased taxation. 
Respondents were willing to pay 30 Euro more in increased taxes per person per year to see a 
permanent nephrologist than a non-permanent (visiting) nephrologist. The provision of 
accommodation required to undertake dialysis in apartments was valued at 70 Euro, and in hotels at 
88 Euro of increased taxation per person per year. The statistically significant model constant, 
implied an overall preference in favour of dialysis in Greenland (valued at 63 Euros).  
 
A DCE in Australia assessed preferences for dialysis modality among 105 pre-dialysis patients and 73 
caregivers.[12] Informed by preliminary research,[13, 14] 3 treatment alternatives for home dialysis, 
in-centre dialysis and non-dialytic conservative care were created. The alternatives were described 
by 7 attributes including average survival time, number of visits per week to hospital for dialysis, 
ability to travel or ‘go away’ on short trips, hours of dialysis per treatment, time of day the dialysis 
can be undertaken, provision of a transport service to attend dialysis or doctors’ appointments, and 
whether there was flexibility to change dialysis and times. Findings reported home-based dialysis 
was chosen 65% of the time and in-centre dialysis 35% of the time. Comparing dialysis versus 
conservative care, 90% of respondents chose a dialysis option and 10% chose a non-dialysis 
(conservative care) option.  In the main analysis for patients, 2 variables for home-based dialysis (life 
expectancy [OR, 1.68], travel restrictions [OR, 0.37]) were significant with another 8 variables non-
significant. Similarly, 1 attribute for in-centre haemodialysis (longer hours [OR, 2.02] was significant. 
Among caregivers, home dialysis was chosen 72% of the time, in-centre dialysis 25% of the time, and 
conservative care in 3%. Moreover, 3 out of 9 variables relating to home dialysis compared to 
conservative care (life expectancy [OR, 1.82], dialysis at night [OR, 0.03], and travel restrictions with 
home dialysis [OR, 0.43]) were significant. Similarly, amongst caregivers when comparing in-centre 
haemodialysis with conservative care 2 out of 11 variables (dialysis at night time [OR, 0.03] and 
hours with in-centre dialysis [OR, 2.67]) were significant. All significant variables were in the 
expected direction. 
 
A second analysis from the same research teams[15] elicited preferences for dialysis versus 
conservative non-dialytic care in Australia. Findings suggested patients preferred dialysis to 
conservative care if dialysis increased average life expectancy (OR, 1.84; 95%CI, 1.57-2.15), if they 
could dialyse during the day or evening rather than during the day only (OR, 8.95; 95% CI, 4.46-
17.97), and if subsidised transport was available (OR, 1.55; 95% CI, 1.24-1.95). Patients were less 
likely to choose dialysis over conservative care if more hospital visits were required (OR, 0.70; 95% 
CI, 0.56-0.88), and with more restrictions on travel (OR, 0.47; 95% CI, 0.36-0.61). Patients would 
forgo 7 months life expectancy to reduce the number of visits to the hospital, and 15 months to 
increase the ability to travel. 
 
Another DCE[16] looked at the preferences of 159 Australian nephrologists for dialysis in elderly 
patients with end-stage kidney disease. The DCE included 10 attributes. Findings indicated all patient 
characteristics (except sex) significantly affected the likelihood of nephrologists recommending 
dialysis. Nephrologists were more likely to recommend dialysis for patients with preserved cognition 
(OR, 68.3, 95% CI: 33.4-140.0), lower comorbidity (OR, 2.1, 95% CI: 1.1-4.1), increased life 
expectancy (OR, 2.8, 95% CI: 2.1-3.7), high current QOL (OR, 2.8, 95% CI: 2.0-3.8), and positive 
patient and family dialysis inclination (OR, 27.5, 95% CI: 16.2-46.8 and OR, 2.0, 95% CI: 1.3-3.3, 
respectively). Nephrologists over 65 years were more likely to recommend dialysis than younger 
nephrologists. Overall, nephrologists would forgo 12 months of patient survival to avoid substantial 
quality of life decreases associated with dialysis. 
 
An ACA[17] investigated preferences among 305 US nephrologists for blood transfusion in chronic 
dialysis patients. The analysis incorporated 10 attributes. Findings presented in terms of relative 
importance of attributes suggested that haemoglobin level (g/dl) accounted for 29% of decision-
making, followed by functional status (16%), cardiovascular disease (12%), clinical scenario (9%), ESA 
status (9%), age (7%), haemoglobin stability over time (6%), kidney transplant eligibility (5%), iron 
indices (4%), and evidence of occult blood in stool: Fecal Occult Blood Test or Fecal Immunochemical 
Test positive (3%). 
 
Combined dialysis, end-of-life & transplantation  
One Canadian DCE,[18] assessed the preferences of 169 patients, 29 caregivers, and 150 healthcare 
professionals. Dialysis-related attributes included ‘Who provides comprehensive day to day care for 
patients on dialysis?’ and ‘How decisions to stop dialysis should be made’. Transplantation attributes 
included ‘How deceased donor kidneys should be allocated for transplantation’, and ‘How should 
live kidneys for transplantation be obtained?’ Other attributes related to ‘end-of-life’ issues 
including ‘When should end-of-life care discussions commence?’ and ‘How much information on 
prognosis and end-of-life care issues should be routinely provided?’ All the attributes were 
significant, with the exception of some levels for the attribute about who provides comprehensive 
day-to-day care on dialysis.  Regression coefficients suggested that for all respondents early ‘end-of-
life care’ discussions (0.72) were preferred to late (0.00); detailed information on prognosis and end-
of-life care was preferred to limited information (0.56 vs 0.00); whereas medical and personal 
decisions (0.34) as opposed to personal decisions only (0.00) was preferred for decisions about 
stopping dialysis.  
 
In relation to how deceased donor kidneys should be allocated, the ‘best match’ approach (0.81) was 
preferred to ‘first come first served’ (0.00). With respect to how live kidneys for transplantation 
should be obtained, receiving an organ from an unknown donor (-0.43), via a paired kidney exchange 
(-0.80), or buying a kidney (-1.93) were less preferable than receiving a kidney from a family member 
or close friend (0.00). For the attribute of providing day-to-day dialysis care, the family physician (-
0.51) was less preferable than ‘family physician and group of kidney specialists’ (0.25), whilst the 
‘advanced nurse practitioner and group of kidney specialists’ was non-significant.  
 
Renal cancer studies 
A DCE assessed 120 patients, 52 family members, and 272 healthcare professionals’ preferences for 
targeted renal cell carcinoma therapy in South Korea.[19] The analysis involved 6 attributes. All the 
attributes were significant at the 1% level for patients and health professionals. Additional months 
of progression-free survival were positively valued at 7-31% in terms of relative importance; 
additional months of bone marrow suppression was negatively valued at 18-36%;  the increased 
likelihood of hand-foot skin reaction was negatively valued at 12-23% ; increased likelihood of 
gastrointestinal perforation was valued at between 4-13%: increased risk of bleeding was valued at 
between 11-14%; and administration by injection versus orally was valued at 13-22% in terms of 
relative importance of attributes according to the stakeholder group. 
 
A second DCE assessed benefit-risk preferences for targeted agents in the treatment of renal cell 
carcinoma in 138 US patients.[20]  The respondents faced questions relating to hypothetical renal 
cell carcinoma profiles. The profiles were defined by attributes including efficacy (progression-free 
survival [PFS]), when overall survival was constant), tolerability effects (fatigue / tiredness, 
diarrhoea, hand-foot syndrome, mouth sores) and serious adverse events (liver failure, blood clot). 
Findings suggested PFS was the most important attribute for patients. The remaining attributes were 
ranked in decreasing order of importance: fatigue / tiredness, diarrhoea, liver failure, hand-foot 
syndrome, blood clot, and mouth sores. A key finding was that to increase PFS by 11 months, 
patients would accept a maximum blood clot risk of 3.1% (95%CI 1.5- 5.3) or liver failure risk of 2.0% 
(95%CI 1.0- 3.3). 
 
Discussion 
The published literature provides important insights about the preferences of key stakeholder 
groups for treatment of kidney disease. The UK transplantation analyses[6, 7] found that allocation 
on the basis of waiting time was important. However other criteria including quality of tissue match, 
quality of life and life expectancy of recipients, recipient age, and whether recipients had child or 
adult dependents were also of importance. Had some of these attributes been specified in the 
Canadian analysis[18] the ‘first come first served’ allocation criterion may have assumed less 
importance as other allocation attributes were valued. An Australian analysis relating to community 
preferences for organ allocation[8] had the advantage that a wide variety of allocation criteria were 
considered. However, its applicability to kidney transplant allocation preferences was unclear 
because it considered preferences for allocating organs in general. Separate Australian analysis[9] 
revealed that the type of donation consent system and availability of family priority for transplants 
did not influence community preferences, although other factors were important.  
 
A US analysis suggested most patients would consider, or accept a transplant at increased risk of 
blood-borne viral infection.[5] Another US analysis[10] demonstrated that frequency and timing of 
dialysis were pertinent and a majority of patients would only switch to 6 sessions from 3 sessions 
weekly for substantive health benefits. A different analysis[11] demonstrated a clear preference, for 
localised dialysis provision within Greenland, at the cost of increased annual taxation. An Australian 
dialysis analyses[12] found that whilst some determinants of dialysis versus conservative dialysis 
could be established for patients and caregiver respondents, many of the hypothesized 
determinants of preferences (e.g. attributes) proved non-significant. Another Australian analysis[15] 
relating to patient preferences for dialysis versus conservative care, concluded patients would forgo 
7 months of life expectancy to reduce visits to the hospital, or 15 months to increase the ability to 
travel. An assessment of Australian Nephrologists’ preferences[16] found they would forgo 12 
months of patient survival in elderly patients to avoid substantial quality of life decreases associated 
with dialysis. Another analysis[17] relating to US Nephrologists’ preferences highlighted the 
importance of clinical considerations relating to blood transfusions in dialysis patients. 
 
A South Korean analysis[19] related to targeted renal cell carcinoma therapy, showed results varied 
considerably between the patient, family, and healthcare professional stakeholder groups. In 
contrast, a US analysis[20] relating to targeted agents in renal cell carcinoma concluded that to 
increase progression-free survival by 11 months, patients would accept a 3.1% blood clot risk or 2% 
liver failure risk. 
 
Looking to the future, several choice studies in nephrology are planned, including patient 
preferences for kidney transplant monitoring by video-conferencing,[21] preferences for outcomes 
after kidney transplantation,[22] and patient and family preferences for home versus facility-based 
dialysis in New Zealand.[23]  
 
Conclusions 
This review has evaluated the content and methodology of choice studies in nephrology. These 
study designs are increasingly used to obtain information about key preferences in kidney 
transplantation and dialysis. In contrast to other methods they provide quantitative information 
about respondents’ trade-offs between conflicting objectives, and can establish how policy-relevant 
preferences vary among stakeholder groups. 
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FIGURE 1: Example of a choice set (scenario) in a DCE of nephrologists’ preferences for dialysis 
recommendation in elderly ESKD patients used in the reviewed DCE analysis cited in the reference 
list by Foote et al 2014.  
 
 
 
 
The attribute levels were allowed to vary across choice sets as set out in table 1. 
 
 
  
Table 1: Characteristics and their levels in the 12 choice sets (scenarios)  
 
Characteristics Levels 
Patient age 75  
85  
90 
Patient gender Male  
Female 
Patient cognitive state Normal  
Somewhat impaired 
Greatly impaired 
Patient comorbid burden Diabetes  
Diabetes/coronary artery disease 
Diabetes/CVD*/peripheral vascular disease 
Patient life expectancy (with dialysis) 1 year  
3 years  
5 years 
Patient QOL (baseline) Low 
Medium 
High 
Patient change in QOL (with dialysis) Expected to decrease 
Expected to be maintained 
Expected to improve 
Family/close person support Low 
Medium 
High 
Patient inclination to dialyse Inclined 
Undecided  
Disinclined 
Family/close person inclination for patient to dialyse Inclined 
Undecided  
Disinclined 
 
*CVD = cerebrovascular disease 
 
  
Table 2. Country of analysis and standardised category (or categories)* of primary choice studies. 
Authors. Country of analysis  Number of 
respondents 
A. Patient 
Consumer 
Experience. 
B. Valuing 
Health 
Outcomes. 
C. 
Investigating 
trade-offs 
health 
outcomes 
and patient 
or consumer 
experience 
factors. 
D. 
Estimating 
utility 
weights 
within the 
QALY 
framework 
E. Job 
Choices for 
preferences 
relating to 
medical 
posts or 
healthcare 
human 
resource 
policy. 
F. 
Developing 
priority 
setting 
frameworks. 
G. Health 
Professional
s 
preferences 
for 
treatment or 
screening 
options for 
patients 
H. Other 
Clark et al 
(2009) UK 
908 patients. 
- -  - -  - - 
Clark et al 
(2012) 
UK 
908 patients, 
41 Carers, 113 
Healthcare 
professionals. 
- -  - -   - 
Davison et al 
(2010) Canada 
169 patients, 
29 Carers.  - - - -   - 
Foote et al 
(2014) 
Australia and New 
Zealand 
159 
Nephrologists - - 
- - - -  - 
Halpern et al 
(2004) USA 
126 patients 
- -  - - - - - 
Howard et al 
(2015a) Australia 
2051 
Community 
respondents 
- -  - -  - - 
Howard et al 
(2015b) Australia 
2005 
Community 
respondents 
- - - - - - -  
Kjaer et al 
(2012) Greenland 
206 Public 
preferences - - - - - 
 - - 
Mohamed et 
al (2011) 
USA (+respondents from 
Australia, Canada, UK) 
138 patients 
- -  - - - - - 
Morton et al 
(2012a) Australia 
105 Patients, 
73 Carers - -  - - - - - 
Morton et al 
(2012b) Australia 
105 Patients 
- -  - - - - - 
Park et al 
(2012) 
South Korea 
120 Patients, 
52 Family 
members, 272 
Healthcare 
professional 
- -  - - -  - 
Reese et al 
(2010) USA 
175 patients 
- -  - -  - - 
Whitman et al 
(2013) USA 
305 
Nephrologists - - - - - -  - 
Total   1 0 9 0 0 6 5 1 
 
A blank cell suggests that the paper does not fulfil this criterion, whereas the symbol  implies that the criterion is met. 
* Standard categories used in prior systematic reviews of DCE studies in the healthcare literature.  
 
 
